Biotech company Arctic Bioscience AS (Euronext Growth Oslo:ABS) reported on Tuesday that analysis of blood samples from its phase 2b HeROPA study showed statistically significant effects of HRO350 compared to placebo on the Systemic Immune-inflammation Index (SII) in patients with mild-to-moderate psoriasis.

More patients treated with HRO350 achieved a 25% or greater reduction in systemic inflammation at both 26 weeks and one year.

Among patients with lower baseline systemic inflammation, these reductions were accompanied by significant improvements in psoriasis skin symptoms and quality of life, as measured by sPGA0/1 and DLQI0/1 scores after one year. The results suggest that screening patients by baseline SII may improve precision in selecting candidates for future trials.

The HeROPA study included over 500 patients across five countries and reported no safety concerns or drug-related serious adverse events. HRO350 was well tolerated throughout the trial.

Arctic Bioscience said the findings align with earlier in vitro data showing HRO350's role in the resolution of inflammation. The company sees strong market potential for HRO350 in mild-to-moderate psoriasis and plans to seek partnerships for further development, noting the drug's potential as a broader anti-inflammatory platform.